Federated Investors Inc. PA decreased its stake in Pfizer Inc. (NYSE:PFE) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,542,728 shares of the biopharmaceutical company’s stock after selling 78,002 shares during the period. Federated Investors Inc. PA’s holdings in Pfizer were worth $82,588,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fusion Family Wealth LLC purchased a new stake in Pfizer during the fourth quarter valued at about $109,000. First National Bank Sioux Falls raised its stake in Pfizer by 108.2% in the third quarter. First National Bank Sioux Falls now owns 3,367 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 1,750 shares during the last quarter. Cornerstone Advisors Inc. raised its stake in Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 541 shares during the last quarter. Gierl Augustine Investment Management Inc raised its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares during the last quarter. Finally, Stanford Investment Group Inc. raised its stake in Pfizer by 11.8% in the fourth quarter. Stanford Investment Group Inc. now owns 4,329 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 456 shares during the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) opened at 34.38 on Tuesday. Pfizer Inc. has a 12-month low of $29.17 and a 12-month high of $37.39. The firm’s 50-day moving average is $33.34 and its 200 day moving average is $32.84. The stock has a market capitalization of $204.63 billion, a P/E ratio of 29.31 and a beta of 0.94.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by $0.03. The company earned $13.60 billion during the quarter, compared to the consensus estimate of $13.64 billion. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. Pfizer’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.53 EPS. On average, equities research analysts forecast that Pfizer Inc. will post $2.55 EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Several analysts have recently issued reports on the stock. BMO Capital Markets reiterated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research note on Tuesday. Sanford C. Bernstein set a $35.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, March 13th. Vetr lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.33 target price for the company. in a research note on Monday, December 26th. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, December 2nd. They issued a “neutral” rating for the company. Finally, Credit Suisse Group AG set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, March 13th. Thirteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $37.32.
In other Pfizer news, insider Rady A. Johnson sold 4,500 shares of the company’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $34.19, for a total value of $153,855.00. Following the transaction, the insider now owns 54,963 shares of the company’s stock, valued at $1,879,184.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Charles H. Hill sold 36,000 shares of the company’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $34.07, for a total value of $1,226,520.00. Following the completion of the transaction, the insider now directly owns 57,329 shares in the company, valued at approximately $1,953,199.03. The disclosure for this sale can be found here. Insiders sold 71,470 shares of company stock worth $2,449,150 in the last ninety days. 0.07% of the stock is owned by corporate insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.